Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience to his new role. He will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.
The appointment signals Scinai’s commitment to strengthening its CDMO capabilities, which are central to the company’s strategy of providing development and manufacturing services to other biotechnology and pharmaceutical companies. Elmalem’s experience is expected to be instrumental in scaling operations at the Yavne facility, which is a key asset for Scinai’s growth. The company also continues to advance its own pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.
Investors can find the latest news and updates relating to SCNI in the company’s newsroom at https://ibn.fm/SCNI. The full press release on the appointment is available at https://ibn.fm/VLt3w.
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on the development of innovative immunology therapies. The company owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) that provides development and manufacturing services to biotechnology and pharmaceutical companies. The appointment of Elmalem is a strategic move to enhance the CDMO’s operational efficiency and capacity, positioning Scinai to better serve its clients and support its own pipeline development.
The Yavne facility is a critical component of Scinai’s business model, as it generates revenue through service contracts while also supporting the company’s internal development programs. By appointing an experienced leader like Elmalem, Scinai aims to optimize the facility’s performance and expand its client base. The company’s dual focus on both its own therapeutics and CDMO services provides a diversified revenue stream and mitigates risk associated with drug development.
Elmalem’s background includes extensive experience in biotech and pharmaceutical operations, which will be valuable in overseeing the technical and engineering aspects of the facility. His previous work as an external consultant for Scinai has already familiarized him with the company’s operations and culture, allowing for a seamless transition into the site head role.
The appointment comes at a time when the CDMO market is experiencing significant growth, driven by increasing demand for outsourced manufacturing services from biotech and pharma companies. Scinai’s expansion of its CDMO platform aligns with this trend, positioning the company to capture a larger share of the market. With Elmalem at the helm of the Yavne facility, Scinai is well-positioned to execute its growth strategy and deliver value to its shareholders.
